Market need Growing demand for noninvasive cancer diagnostics and personalized therapy monitoring presents a customer base in oncology clinics and hospital systems seeking CTC isolation and analysis solutions.

Clinical value CytoCatch platform enables early cancer detection and treatment personalization, which can drive adoption among oncologists and pathology labs aiming to improve patient outcomes and reduce time-to-treatment.

Small company leverage With a focused product line and a lean team, Delee can pursue targeted pilot programs at mid to large healthcare providers, leveraging case studies to win broader deployments.

Strategic partnerships Potential collaborations with established biotech distributors or major diagnostic device integrators (e.g., those serving Bio-Rad, Thermo Fisher, Agilent customers) could accelerate market reach and service enablement.

Revenue opportunities Upsell and expansion opportunities exist in consumables, software analytics enhancements of the imaging system, service contracts, and volume-based pricing as adoption scales in oncology centers.